CAS 229016-73-3: Pyridinio, 4-[2-[[(6R,7R)-2-carboxi-7-[[(2Z)-2-(etoximino)-2-[5-(fosfonoamino)-1,2,4-tiadiazol-3-il]acetil]amino]-8-oxo-5-tia-1-azabiciclo[4.2.0]oct-2-en-3-il]tio]-4-tiazolil]-1-metil-, sal interna

Ceftaroline fosamil is an advanced antibiotic, which is a cephalosporin derived from synthetic sources with a broad spectrum of activity. It is a prodrug that, once metabolized, becomes active in the body, binding to penicillin-binding proteins (PBPs) of bacteria. This binding inhibits the proteins responsible for cell wall synthesis, leading to bacterial cell lysis and death. The uses of Ceftaroline fosamil are primarily focused on the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). It is particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) and other multidrug-resistant organisms. Ceftaroline fosamil's enhanced binding affinity to PBPs, especially PBP2a found in resistant strains, makes it a crucial asset in combating serious and resistant bacterial infections. Its clinical applications are pivotal in settings where resistance to traditional antibiotics poses significant therapeutic challenges, thus providing an effective alternative for healthcare professionals facing such issues. As antibiotic resistance remains a critical concern in medical science, Ceftaroline fosamil's role continues to be of high interest and relevance.

Ceftaroline fosamil (TAK-599) is a cephalosporin-derived MRSA antibiotic prodrug.

Applications Ceftaroline Fosamil Inner salt-d3 is labelled Ceftaroline Fosamil inner salt (C243970) which is a cephalosporin antibiotic. It is active against methicillin-resistant Staphylococcus aureus (MRSA) and Gram-positive bacteria. References Kanafani, Z., et al.: Future Microbiology, 4, 25 (2009); Parish, D,, et al.: Curr. Opinion Invest. Drugs, 9, 201 (2000)